APA (7th ed.) Citation

PA, A., M, C., J, B., M, P., C, P., L, P., . . . G, P. (2024). Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature communications, 15(1), 146. https://doi.org/10.1038/s41467-023-44475-6

Chicago Style (17th ed.) Citation

PA, Ascierto, et al. "Sequential Immunotherapy and Targeted Therapy for Metastatic BRAF V600 Mutated Melanoma: 4-year Survival and Biomarkers Evaluation from the Phase II SECOMBIT Trial." Nature Communications 15, no. 1 (2024): 146. https://doi.org/10.1038/s41467-023-44475-6.

MLA (9th ed.) Citation

PA, Ascierto, et al. "Sequential Immunotherapy and Targeted Therapy for Metastatic BRAF V600 Mutated Melanoma: 4-year Survival and Biomarkers Evaluation from the Phase II SECOMBIT Trial." Nature Communications, vol. 15, no. 1, 2024, p. 146, https://doi.org/10.1038/s41467-023-44475-6.